AstraZeneca PLC (AZN)
AZN trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | AZN on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United Kingdom |
| IPO year | 2026 |
| SEC CIK | 0000901832 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | United Kingdom |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $58.7B |
| Net income | $10.2B |
| Operating income | $13.7B |
| Net margin | 17.4% |
| Operating margin | 23.4% |
| Revenue growth | +8.6% |
| Cash | $5.7B |
| Total assets | $114.1B |
| P/E (computed) | 27.9× |
| P/S (computed) | 4.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-02-24 |
| Cash and burn | $5.7B cash; operating cash flow $3.6B a quarter. | Report 2025-12-31 |
| Shares outstanding | 1,550,907,927 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | 1; latest 1-for-2 on 2026-02-02 | Source 2026-02-02 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2026-05-28 |
| Auditor | PricewaterhouseCoopers LLP, London, United Kingdom | PCAOB Form AP 2026-03-31 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $3K, sold $2.2M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $58.7B | $10.2B | $14.6B | $5.7B | $29.6B | $58.7B | 20-F 2026-02-24 |
| FY 2024 2024-12-31 | $54.1B | $7.0B | $11.9B | $5.5B | $30.3B | $54.1B | 20-F 2026-02-24 |
| FY 2023 2023-12-31 | $45.8B | $6.0B | $10.3B | $5.8B | $28.6B | $45.8B | 20-F 2026-02-24 |
| FY 2022 2022-12-31 | $44.4B | $3.3B | $9.8B | $6.2B | $29.2B | $44.4B | 20-F 2025-02-18 |
| FY 2021 2021-12-31 | $37.4B | $112.0M | $6.0B | $6.3B | $30.8B | $37.4B | 20-F 2024-02-20 |
| FY 2020 2020-12-31 | $26.6B | $3.2B | $4.8B | $7.8B | $20.4B | $26.6B | 20-F 2023-02-21 |
| FY 2019 2019-12-31 | $24.4B | $1.3B | $3.0B | $5.4B | $18.2B | $24.4B | 20-F 2022-02-22 |
| FY 2018 2018-12-31 | $22.1B | $2.2B | $2.6B | $4.8B | $19.1B | $22.1B | 20-F 2021-02-16 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B2 | 2026-02-27 |
| Latest annual report | 20-F | 2026-02-24 |
| Latest quarterly / interim BAXFENDY RECOMMENDED FOR APPROVAL IN THE EU | 6-K | 2026-11-16 |
Source: SEC EDGAR submissions feed, 1,006 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.1% |
| 1 month | +18.4% |
| 3 months | +17.3% |
| Year to date | +0.3% |
| 1 year | +4.1% |
| From 52-week high | -11.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NVS | Novartis AG | $160.20 | -0.19% | $305.7B |
| MRK | Merck & Company Inc. Common Stock (new) | $144.46 | -2.23% | $356.1B |
| ABT | Abbott Laboratories | $107.45 | -0.99% | $186.1B |
| NVO | Novo Nordisk A/S | $41.60 | -0.07% | $184.2B |
| PFE | Pfizer Inc. | $28.86 | -0.10% | $164.5B |
| ABBV | AbbVie Inc. | $294.55 | -0.16% | $520.7B |
| VRTX | Vertex Pharmaceuticals Incorporated | $537.79 | -0.15% | $136.4B |
| BMY | Bristol-Myers Squibb Company | $62.93 | -0.79% | $128.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier